Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
I. L. Santoro, R. A. Ybanez, S. Jamnik, C. Uehara, A. L. G. Fernandes (São Paulo, SP, Brazil). Trends of the proportion of small-cell lung cancer (SCLC) over the last 20 year: a university medical center experience. Eur Respir J 2007; 30: Suppl. 51, 2509

Member's Comments

No comment yet.

Related content which might interest you: Comparison of non-small cell lung cancer (NSCLC) management and survival in 1995 and 2005 at a London teaching hospital Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Survival with in-operable non-small cell lung cancer in U.K district general hospital: Is chemotherapy better than active supportive care? Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Locally advanced and metastatic lung cancer management delay: Tunisian department experience Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Direct to surgery treatment of suspected lung cancer – results from a UK lung cancer multidisciplinary team (MDT) Source: Virtual Congress 2021 – Innovation in thoracic surgery Year: 2021 Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Patient and doctor delays in the diagnosis and treatment of non-small cell lung cancer in Turkey Source: Annual Congress 2013 –Quality management in thoracic oncology Year: 2013 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Integration of palliative care from the very beginning to the very end in a patient with metastasised non-small cell lung cancer Source: International Congress 2018 – CC3 Lung cancer: personalised treatment and palliative care Year: 2018 Survival outcomes in advance non-small cell lung cancer – A developing country scenario Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening Source: Eur Respir J, 54 (2) 1802221; 10.1183/13993003.02221-2018 Year: 2019 A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015 EGF-receptor mutation in non-small cell lung cancer – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Expressed wishes and incidence of euthanasia in advanced lung cancer patients}, Source: Eur Respir J 2012; 40: 949-956 Year: 2012